脑出血后预防性抗癫痫药物处方的演变:多中心研究
该研究基于美国4个学术医疗中心2007–2012年的电子病历数据,纳入3422例脑出血患者,观察新证据和指南修订前后预防性抗癫痫药物处方的变化;发现苯妥英使用从2009年的9.6%降至2012年的2.2%,左乙拉西坦从2007年的15.1%升至2012年的35%,且左乙拉西坦使用在不同机构间差异显著。
要点
- 苯妥英使用率显著下降,左乙拉西坦使用率翻倍以上。
- 左乙拉西坦使用在不同机构间差异大(6.7%–29.8%)。
- 指南修订需预见并处理替代药物的使用变化。
核心结论
- 导致预防性抗癫痫药物处方指南修订的新数据与苯妥英使用显著减少在时间上相关,可能减少不良结局。
- 左乙拉西坦使用相应增加,尽管对其结局影响了解有限。
研究设计与样本
- 观察性研究,使用美国大型都市区4个学术医疗中心的电子病历数据。
- 纳入2007年至2012年诊断的3422例脑出血患者。
主要发现
- 苯妥英使用从2009年的9.6%降至2012年的2.2%(p < 0.00001)。
- 左乙拉西坦使用从2007年的15.1%升至2012年的35%(p < 0.00001)。
- 左乙拉西坦使用在4个机构间从6.7%到29.8%不等(p < 0.00001)。
临床怎么用
- 临床医生在为脑出血患者处方预防性抗癫痫药物时,应关注证据更新和指南变化。
- 需注意不同机构间左乙拉西坦使用差异,评估替代药物的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prophylactic medications can be a source of preventable harm, potentially affecting large numbers of patients. Few data exist about how clinicians change prescribing practices in response to new data and revisions to guidelines about preventable harm from a prophylactic medication. We sought to determine the changes in prescribing practice of seizure medications for patients with intracerebral hemorrhage (ICH) across a metropolitan area before and after new outcomes data and revised prescribing guidelines were published. METHODS: We conducted an observational study using electronic medical record data from 4 academic medical centers in a large US metropolitan area. RESULTS: A total of 3,422 patients with ICH, diagnosed between 2007 and 2012, were included. In 2009, after a publication found an association of phenytoin with higher odds of dependence or death, the use of phenytoin declined from 9.6% in 2009 to 2.2% in 2012 (p < 0.00001). Conversely, the use of levetiracetam more than doubled, from 15.1% in 2007 to 35% in 2012 (p < 0.00001). Use of levetiracetam varied among the 4 institutions from 6.7% to 29.8% (p < 0.00001). CONCLUSIONS: New data that led to revised prescribing guidelines for prophylactic seizure medications for patients with ICH were temporally associated with a significant decrease in use of the medication, potentially reducing adverse outcomes. However, a corresponding increase in the use of an alternative medication, levetiracetam, occurred despite limited knowledge about its potential effects on outcomes. Future guideline changes should anticipate and address alternatives.
引用
- Naidech AM, Beaumont J, Jahromi B, et al. Evolving use of seizure medications after intracerebral hemorrhage: A multicenter study. Neurology. 2016. PMID: 27864524. doi:10.1212/WNL.0000000000003461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。